Dependence on Outsourced Providers for Research and Development, Manufacturing and Clinical Trials, and Uncertainty in Securing Alternatives
First written in FY2024. 1 of 2 entries say "Mitigated", first in FY2025. Latest entry: FY2025.
0 other companies' latest entry also says "Mitigated".
- FY2025MitigatedAnnual report
「To address this risk, we are working to secure multiple alternative service providers. However, there is uncertainty as to whether outsourcing contracts can be concluded at an appropriate time, and equivalent service quality is not guaranteed. Accordingly, switching to an alternative provider could involve time, risks and additional costs.」
The company stated that it would address its dependence on external service providers by securing multiple alternative providers. However, uncertainty remains regarding quality, timing and additional costs during the transition. - FY2024First statedAnnual report
「If a contract with an external service provider is terminated for an unforeseen reason, the contract is amended on terms unfavorable to us, or the provider encounters difficulties in performing its services, our business activity plans could undergo significant changes.」
The risks associated with outsourcing pharmacology, nonclinical studies, investigational drug manufacturing and clinical trials include contract termination or service suspension by providers, quality differences and switching costs.